Chen Jialiang, Xue Dongying, Gao Fangyuan, Tao Le, Li Yuxin, Zhang Qun, Wang Rui, Sun Le, Yang Xue, Liu Yao, Zhu Bingbing, Niu Shuaishuai, Wang Xianbo
Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University.
Department of infectious disease, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Eur J Gastroenterol Hepatol. 2018 Nov;30(11):1352-1360. doi: 10.1097/MEG.0000000000001186.
The biochemical response after ursodeoxycholic acid (UDCA) treatment contributes toward predicting the prognosis for primary biliary cholangitis (PBC) patients. This study aimed to establish a score model that can be used for predicting the biochemical response.
A total of 218 patients in the derivation group and 66 patients in the verification group were enrolled. Response endpoints were based on the Barcelona criteria combined with the Paris I criteria. We determined independent factors of the biochemical response by univariate and multivariate analyses. Then, we established a predictive score model on the basis of regression coefficients after adjusted multivariate analyses.
The median follow-up duration in the derivation and the verification group was 12.9 and 12.2 months, respectively. Multivariate logistic regression analysis after adjusting for sex and age indicated that First-UDCA treatment [odds ratio (OR)=2.543, 95% confidence interval (CI): 1.234-5.240, P=0.011], baseline alanine aminotransferase level (OR=1.265, 95% CI: 1.089-1.471, P=0.002), and baseline total bilirubin level (OR=0.571, 95% CI: 0.420-0.776, P<0.001) were independent factors that influenced the biochemical response in PBC patients after 1 year of UDCA treatment. Therefore, the resulting biochemical response prediction score model represented the sum of the points corresponding to these three variables. The area under the receiver operating characteristic curve of the score model in the derivation group and the verification group was 0.763 (95% CI: 0.701-0.817, P<0.001) and 0.798 (95% CI: 0.681-0.887, P<0.001), respectively.
We developed and verified an easy-to-use scoring model for the first time, which showed excellent predictive value for the biochemical response in PBC patients.
熊去氧胆酸(UDCA)治疗后的生化反应有助于预测原发性胆汁性胆管炎(PBC)患者的预后。本研究旨在建立一个可用于预测生化反应的评分模型。
共纳入218例推导组患者和66例验证组患者。反应终点基于巴塞罗那标准并结合巴黎I标准。我们通过单因素和多因素分析确定生化反应的独立因素。然后,在调整后的多因素分析基础上,根据回归系数建立预测评分模型。
推导组和验证组的中位随访时间分别为12.9个月和12.2个月。在对性别和年龄进行调整后的多因素逻辑回归分析表明,首次UDCA治疗[比值比(OR)=2.543,95%置信区间(CI):1.234 - 5.240,P = 0.011]、基线丙氨酸氨基转移酶水平(OR = 1.265,95% CI:1.089 - 1.471,P = 0.002)以及基线总胆红素水平(OR = 0.571,95% CI:0.420 - 0.776,P < 0.001)是影响UDCA治疗1年后PBC患者生化反应的独立因素。因此,所得的生化反应预测评分模型代表这三个变量对应的分数之和。该评分模型在推导组和验证组的受试者工作特征曲线下面积分别为0.763(95% CI:0.701 - 0.817,P < 0.001)和0.798(95% CI:0.681 - 0.887,P < 0.001)。
我们首次开发并验证了一个易于使用的评分模型,该模型对PBC患者的生化反应具有出色的预测价值。